On July 30, 2026, the US Food and Drug Administration released a draft guidance expanding its recommendations on container closure systems and device constituent parts for biosimilar and interchangeable biosimilar products. Issued jointly by the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) under docket FDA-2026-D-4272, the document is marked Draft Level 1 guidance with non-binding recommendations, explicitly "not for implementation" while the agency takes public comment.
The draft builds directly on two existing FDA guidances: Q.I.4 of Questions and Answers on Biosimilar Development and the BPCI Act and Considerations in Demonstrating Interchangeability With a Reference Product. It clarifies and expands agency expectations around the delivery devices and container closure systems that sponsors propose for 351(k) presentations, an area where packaging and device choices can shape both the filing strategy and the interchangeability case.
What does the draft add to the existing biosimilar guidance?
The new text fleshes out the device and packaging recommendations that Q.I.4 only outlined at a high level, giving sponsors more concrete expectations for container closure systems and device constituent parts in biosimilar and interchangeable biosimilar filings. Where the earlier Q&A pointed sponsors toward general considerations for delivery devices and container closure systems, this draft guidance turns those considerations into a fuller, dedicated framework.
For sponsors, the practical shift is that device constituent parts, the autoinjector, prefilled syringe or pen component of a combination product, and the container closure system that contacts the drug, now have an expanded, consolidated reference. The guidance is intended to help applicants develop these elements for proposed biosimilar and interchangeable products, rather than piecing together expectations from question-level answers and a separate interchangeability document.
Who has to act, and on what timeline?
CMC and regulatory leads at 351(k) biosimilar sponsors, and the container closure and device partners they rely on, are the directly affected parties. Named biosimilar sponsors operating in the US market include Amgen, Sandoz, Celltrion, Pfizer, Samsung Bioepis, Biocon and Organon, while the device and packaging side spans partners such as BD, West Pharmaceutical Services, Ypsomed and SHL Medical. None face a binding compliance date from this document: it is a draft, and FDA stresses its recommendations are non-binding.
The concrete near-term action is the comment window. FDA accepts comments on the draft through the regulations.gov docket FDA-2026-D-4272, and written comments can also be mailed to Dockets Management (5630 Fishers Lane, Rm 1061, Rockville, MD 20852) identified with the docket number. Under 21 CFR 10.115(g)(5), comments may be submitted at any time, but sponsors and device partners who want to shape the final recommendations should file during the open comment period.
How does this fit with interchangeability strategy?
The draft ties device constituent part and container closure choices back to the interchangeability question. Because an interchangeable biosimilar may be substituted for the reference product at the pharmacy level without the prescriber's intervention, the presentation, device performance and container closure integrity carry weight beyond a standard biosimilar filing. By expanding on the interchangeability guidance alongside Q.I.4, FDA is signalling that device and packaging decisions should be planned with the interchangeability endpoint in view, not bolted on late.
| FDA guidance | What it covers | Role of the July 2026 draft |
|---|---|---|
| Q&A on Biosimilar Development and the BPCI Act (Q.I.4) | General considerations for delivery devices and container closure systems | Expanded and clarified by the new draft |
| Considerations in Demonstrating Interchangeability With a Reference Product | Interchangeability expectations for biosimilars | Device constituent part angles expanded by the new draft |
| July 2026 draft (FDA-2026-D-4272) | Container closure systems and device constituent parts for biosimilar and interchangeable products | Consolidates and extends both into a dedicated framework |
What should sponsors do before the guidance is finalized?
Even as a draft, the document is a signal of where FDA expectations are heading. Sponsors with 351(k) presentations in development should map their current container closure system and device constituent part plans against the expanded recommendations now, so that late-stage redesigns are avoidable once the guidance is finalized. Device and packaging partners should brief their biosimilar clients on the delta between Q.I.4 and this draft.
Continuous, per-jurisdiction real-time monitoring surfaces this kind of FDA guidance the moment it publishes, so CMC and regulatory teams can align development plans before a draft hardens into a final expectation. The draft guidance PDF and the docket are the two primary references for any internal review.
Take advantage of this real-time watch
Next steps for affected teams: confirm whether your 351(k) presentation's container closure system and device constituent part strategy aligns with the expanded recommendations; assign a reviewer to the draft PDF and the docket; and decide whether to file comments before the window closes. Brief CMC, regulatory affairs and the device partner together, since the guidance crosses all three.
